REGENXBIO announces first FDA approval of gene therapy based on its proprietary NAV®
REGENXBIO announced the first FDA approval of a gene therapy that leverages REGENXBIO's proprietary NAV Technology Platform, Novartis AG's ZOLGENSMA® (onasemnogene abeparvovec-xioi; AVXS-101). ZOLGENSMA was approved by the FDA as a one-time infusion for pediatric patients with SMA. May 24, 2019